Diagnosis of Adrenal Insufficiency Using the GHRP-6 Test: Comparison with the Insulin Tolerance Test in Patients with Hypothalamic-Pituitary-Adrenal Disease

Abstract

The insulin tolerance test (ITT) is considered the gold standard for the diagnosis of adrenal insufficiency (AI). However, the test is unpleasant to perform and has the risk of serious complications. We therefore evaluated the clinical applicability of GHRP6, which is a known activator of the hypothalamic-pituitary-adrenal (HPA) axis, to test for AI. For this purpose a comparative clinical study was designed. Forty-nine patients with suspected dysfunction of the HPA axis and 20 healthy controls were enrolled. The ITT was performed in patients, and GHRP6 (1 μg/kg) testing in patients and controls. Serum cortisol over 90 min after GHRP6, in comparison to the ITT, was the main outcome measure. Thirty-one patients had a peak cortisol response of less than 500 nmol/l during ITT and were considered adrenal insufficient. For GHRP6, the mean cortisol peak was 227±25.7 nmol/l in the AI group versus 395±35.3 nmol/l in the adrenal sufficient (AS) group. ROC analysis of peak cortisol levels during GHRP6 test suggested an optimal threshold of 299 nmol/l for the diagnosis of AI (Sens. 71.0%, Spec. 77.8%). Applying upper (416 nmol/l) and lower (137 nmol/l) thresholds with high specificities in combination with early morning cortisol established the diagnosis in nearly half of the patients, even when the GHRP6 test is limited to 30 min duration. GHRP6 led to significant activation of the HPA axis with no detectable side effects, but had limited accuracy in comparison to the ITT.

growth hormone secretagogues - ghrelin - insulin tolerance test

References

• 1 Watts NB, Tindall GT. Rapid assessment of corticotropin reserve after pituitary surgery.  JAMA. 1988;  259 708-711
• 2 Streeten DH, Anderson Jr GH, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test.  J Clin Endocrinol Metab. 1996;  81 285-290
• 3 Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.  J Clin Endocrinol Metab. 2003;  88 4193-4198
• 4 Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides.  Eur J Endocrinol. 1997;  136 445-460
• 5 Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt Jr MJ, Fisher MH, Nargund RP, Patchett AA. Peptidomimetic regulation of growth hormone secretion.  Endocr Rev. 1997;  18 621-645
• 6 Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.  Neuroendocrinology. 1995;  61 584-589
• 7 Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.  J Clin Endocrinol Metab. 1996;  81 4338-4341
• 8 Rahim A, O’Neill PA, Shalet SM. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.  Clin Endocrinol (Oxf). 1999;  50 77-84
• 9 Alaioubi B, Mann K, Petersenn S. Diagnosis of growth hormone deficiency in adults: provocative testing with GHRP6 in comparison to the insulin tolerance test.  Horm Metab Res. 2009;  41 238-243
• 10 Korbonits M, Kaltsas G, Perry LA, Grossman AB, Monson JP, Besser GM, Trainer PJ. Hexarelin as a test of pituitary reserve in patients with pituitary disease.  Clin Endocrinol (Oxf). 1999;  51 369-375
• 11 Codd EE, Shu AY, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites.  Neuropharmacology. 1989;  28 1139-1144
• 12 Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH. A receptor in pituitary and hypothalamus that functions in growth hormone release.  Science. 1996;  273 974-977
• 13 Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.  J Clin Endocrinol Metab. 1999;  84 2489-2495
• 14 Korbonits M, Little JA, Forsling ML, Tringali G, Costa A, Navarra P, Trainer PJ, Grossman AB. The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants.  J Neuroendocrinol. 1999;  11 521-528
• 15 Hirotani C, Oki Y, Ukai K, Okuno T, Kurasaki S, Ohyama T, Doi N, Sasaki K, Ase K. ACTH releasing activity of KP-102 (GHRP-2) in rats is mediated mainly by release of CRF.  Naunyn Schmiedebergs Arch Pharmacol. 2005;  371 54-60
• 16 Arvat E, Ramunni J, Maccagno B, Giordano R, Broglio F, Deghenghi R, Boscaro M, Ghigo E. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.  Neuroendocrinology. 1999;  70 200-206
• 17 Maccario M, Veldhuis JD, Broglio F, Vito LD, Arvat E, Deghenghi R, Ghigo E. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.  Eur J Endocrinol. 2002;  146 310-318
• 18 Pecori Giraldi F, Bucciarelli LG, Saccani A, Scacchi M, Pesce S, Losa M, Cavagnini F. Ghrelin stimulates adrenocorticotrophic hormone (ACTH) secretion by human ACTH-secreting pituitary adenomas in vitro.  J Neuroendocrinol. 2007;  19 208-212
• 19 Barreiro ML, Pinilla L, Aguilar E, Tena-Sempere M. Expression and homologous regulation of GH secretagogue receptor mRNA in rat adrenal gland.  Eur J Endocrinol. 2002;  147 677-688
• 20 Ueberberg B, Unger N, Sheu SY, Walz MK, Schmid KW, Saeger W, Mann K, Petersenn S. Differential expression of ghrelin and its receptor (GHS-R1a) in various adrenal tumors and normal adrenal gland.  Horm Metab Res. 2008;  40 181-188
• 21 Arlt W, Allolio B. Adrenal insufficiency.  Lancet. 2003;  361 1881-1893
• 22 Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency.  Ann Intern Med. 2003;  139 194-204
• 23 Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test.  Eur J Endocrinol. 2009;  160 9-16
• 24 Petersenn S, Jung R, Beil FU. Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test.  Eur J Endocrinol. 2002;  146 667-672
• 25 Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test.  J Clin Endocrinol Metab. 1998;  83 2350-2354
• 26 Hagg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency.  Clin Endocrinol (Oxf). 1987;  26 221-226
• 27 Jones SL, Trainer PJ, Perry L, Wass JA, Bessser GM, Grossman A. An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year.  Clin Endocrinol (Oxf). 1994;  41 123-128

Correspondence